EchoSolv AS vs qXR-CTR
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your primary need is highly accurate, AI-powered clinical decision support for identifying patients at risk of severe aortic stenosis from echocardiogram measurements. This tool is ideal for cardiology departments seeking to enhance the efficiency and consistency of their echo interpretations, providing a rapid second-reader function to prioritize studies for closer review.
View EchoSolv AS →Choose qXR-CTR if…
Choose qXR-CTR if you require an automated, AI-driven solution for measuring the cardiothoracic ratio from chest X-ray images to quickly assess heart size and potential heart failure risk. This tool is particularly well-suited for radiology departments or emergency settings where rapid, initial screening for cardiac enlargement from chest X-rays can aid in patient triage and further diagnostic planning.
View qXR-CTR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | qXR-CTR |
|---|---|---|
| Deployment | Cloud-based | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
qXR-CTRTool B (qXR-CTR) offers a slightly broader range of usability features, including multilingual support, mobile and desktop access via an app, and structured reports in DICOM and JSON formats. While Tool A (EchoSolv AS) emphasizes seamless integration into existing workflows and ultra-fast processing, Tool B's additional features enhance its adaptability and ease of use for a wider range of clinical users and settings.
Clinical Value
EchoSolv ASBoth tools are FDA-cleared and provide significant clinical value. However, Tool A (EchoSolv AS) has demonstrated superior accuracy in identifying severe aortic stenosis, even outperforming human interpretation in studies, and has shown to reduce missed diagnoses and address gender bias in diagnosis. This direct impact on improving the diagnosis of a severe, treatable condition, coupled with its proven ability to outperform human diagnosis, gives it a slight edge in clinical value.
Pricing & Value
EchoSolv ASWhile both tools require direct contact for pricing, Tool A (EchoSolv AS) provides more transparency regarding its business model, indicating a subscription-based model and a clear pathway for US reimbursement codes. This offers healthcare providers a more defined understanding of the potential financial framework and value proposition compared to Tool B's undisclosed pricing.
Enterprise Readiness
qXR-CTRTool B (qXR-CTR) offers superior enterprise readiness due to its flexible deployment options, supporting cloud, on-premise, and hybrid models, which caters to diverse institutional IT infrastructures. While Tool A (EchoSolv AS) highlights seamless PACS integration and no EMR requirement, Tool B's broader deployment flexibility and extensive list of integration partners suggest a more robust and adaptable solution for large-scale enterprise adoption.
Innovation
EchoSolv ASBoth tools are innovative in their application of AI. However, Tool A (EchoSolv AS) demonstrates a more unique and potentially impactful innovation by utilizing 'measurement-based AI' that analyzes numerical data from echocardiogram reports rather than raw images, and specifically avoids LVOT measurements, which can be a source of variability. Its use of a mixture density network to model uncertainty and exclusive access to a large mortality database further highlights advanced technological innovation.
Support & Docs
TieNeither the provided structured facts nor the web search results offered specific details regarding customer support channels, service level agreements, or publicly available documentation (user manuals, FAQs, knowledge bases) for either EchoSolv AS or qXR-CTR. Therefore, it is not possible to distinguish between the two on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | qXR-CTR |
|---|---|---|
| Product Name | EchoSolv AS | qXR-CTR |
| Company | Echo IQ | Qure.ai Technologies |
| Primary AI Function/Purpose | AI-powered clinical decision support platform that analyzes echocardiograms to identify patients at risk for severe aortic stenosis. | AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. |
| Input Data Type / Analysis Method | Measurement-based AI (analyzes numerical measurements, not images) from echocardiograms. | Automates measurement of cardiothoracic ratio (CTR) from chest X-ray images. |
| Integration | Designed to fit existing workflows (no EMR integration required, integrates with PACS). | Not specified |
| Risk Detection Speed | Ultra-fast risk detection (under 3 seconds) | Not specified |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and qXR-CTR.